Compare stocks

Evaluate stocks side by side, to find the best fit for your investment goals.
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.
View stock
VS
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
View stock

Stock highlights

Stock comparison highlights
Stock name
VistaGen Therapeutics Inc.Eli Lilly
Last price
$0.18$1,427.28
Currency
USD
USD
$8.1M$1.3T
-46.65
-$1.66$30.81
0.330.39
0$6.69
00.48%
Sector
HealthHealth
Employees
4150,000
Ticker
$VTGN$LLY
Primary listing
NASDAQNYSE

Performance

CumulativeRolling yearsLump sum investment

Invest in $VTGN or $LLY on Lightyear

Save on broker fees and invest in 6000+ stocks and funds. When you invest, your capital is at risk.